Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab

NCT00933335 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Non-Hodgkin

Interventions

BIOLOGICAL: Tositumomab and Iodine I 131 Tositumomab

Sponsor

GlaxoSmithKline